[{"id":"050cad85-632c-4a3d-8dc0-6b7c173500dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03796884","created_at":"2023-10-19T11:12:17.673Z","updated_at":"2024-07-02T16:35:06.193Z","phase":"Phase 2","brief_title":"Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer","source_id_and_acronym":"NCT03796884","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" MYC • PCNA • AXIN1","pipe":" | ","alterations":" PCNA expression","tags":["MYC • PCNA • AXIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PCNA expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 10/30/2019","start_date":" 10/30/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-03"},{"id":"ef5f595b-9e34-4513-9b8d-50b1aa6a34da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03176381","created_at":"2021-01-18T15:39:48.196Z","updated_at":"2024-07-02T16:35:29.387Z","phase":"","brief_title":"Tissue Predictors of Abiraterone Benefit","source_id_and_acronym":"NCT03176381","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" YAP1 • PCNA","pipe":" | ","alterations":" YAP1 positive • PCNA expression","tags":["YAP1 • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YAP1 positive • PCNA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 05/05/2017","start_date":" 05/05/2017","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-11-14"},{"id":"3954a594-f2fe-4b40-b323-eba48a55d9f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03987568","created_at":"2021-01-18T19:36:28.324Z","updated_at":"2024-07-02T16:35:58.771Z","phase":"","brief_title":"Characterize Tumor Hypoxia by Magnetic Resonance Imaging","source_id_and_acronym":"NCT03987568","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" FASN • PCNA","pipe":" | ","alterations":" PCNA expression","tags":["FASN • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PCNA expression"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/10/2019","start_date":" 07/10/2019","primary_txt":" Primary completion: 11/15/2021","primary_completion_date":" 11/15/2021","study_txt":" Completion: 11/15/2021","study_completion_date":" 11/15/2021","last_update_posted":"2022-12-21"},{"id":"72d682b6-71cf-4384-a45e-35ed7d763de8","acronym":"IMP3PCNA","url":"https://clinicaltrials.gov/study/NCT05293327","created_at":"2022-03-24T14:52:53.807Z","updated_at":"2024-07-02T16:36:14.234Z","phase":"","brief_title":"IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate","source_id_and_acronym":"NCT05293327 - IMP3PCNA","lead_sponsor":"Sohag University","biomarkers":" PCNA","pipe":" | ","alterations":" PCNA expression","tags":["PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PCNA expression"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-04-01"},{"id":"a23f867a-7906-432e-89da-e08a603a14c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01938638","created_at":"2021-01-18T08:46:22.936Z","updated_at":"2025-02-25T17:07:03.748Z","phase":"Phase 1","brief_title":"Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer","source_id_and_acronym":"NCT01938638","lead_sponsor":"Bayer","biomarkers":" MYC • PCNA","pipe":" | ","alterations":" MYC expression • PCNA expression","tags":["MYC • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression • PCNA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atuveciclib (BAY 1143572)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 09/26/2013","start_date":" 09/26/2013","primary_txt":" Primary completion: 08/17/2016","primary_completion_date":" 08/17/2016","study_txt":" Completion: 09/19/2016","study_completion_date":" 09/19/2016","last_update_posted":"2017-10-20"},{"id":"3d38fdc0-92a6-41ab-9768-ebd18f75b59e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00073073","created_at":"2021-01-18T00:11:27.292Z","updated_at":"2024-07-02T16:37:32.131Z","phase":"Phase 2","brief_title":"Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer","source_id_and_acronym":"NCT00073073","lead_sponsor":"Georgetown University","biomarkers":" BRCA1 • BRCA2 • PCNA • TFF1 • LEP","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PCNA expression","tags":["BRCA1 • BRCA2 • PCNA • TFF1 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PCNA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e exemestane • celecoxib oral"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 11/01/2003","start_date":" 11/01/2003","primary_txt":" Primary completion: 12/01/2011","primary_completion_date":" 12/01/2011","study_txt":" Completion: 12/01/2011","study_completion_date":" 12/01/2011","last_update_posted":"2016-05-17"}]